Not time to abandon use of local vaginal hormone therapies

JoAnn V. Pinkerton, Andrew M. Kaunitz, JoAnn E. Manson
Menopause (New York, N.Y.) · 2018 · vol. 25(8) , pp. 855–858 · doi:10.1097/gme.0000000000001142 · PMID:29894370 · W2807980208
Other OA: closed CC0
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-08-02 ⓘ

This review examines the current evidence on local vaginal hormone therapies, concluding that their established safety and efficacy profile supports continued use for managing genitourinary syndrome of menopause.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Pinkerton, JoAnn V. MD, FACOG, NCMP; Kaunitz, Andrew M. MD, FACOG, NCMP; Manson, JoAnn E. MD, DrPH, FACP, NCMP

My notes (saved in your browser only)

MeSH descriptors

Estrogen Replacement Therapy Estrogens Female Urogenital Diseases Vaginal Diseases Administration, Intravaginal Estrogen Replacement Therapy Estrogens Female Female Urogenital Diseases Female Urogenital Diseases Humans Middle Aged Postmenopause Vagina Vagina Vagina Vaginal Diseases Vaginal Diseases

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

References (20)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:22:15.942320+00:00
unpaywall
last seen: 2026-10-25T06:24:14.523685+00:00
License: CC0 · commercial use OK